Serum Levels of Prostate Specific Antigen, Free PSA, [‐2]proPSA, fPSA/tPSA Ratio, Prostate Health Index, and Glycosylation Patterns of Free PSA in Patients With Benign Prostatic Hyperplasia Pharmacotherapy: Limitations and Future Directions

Dettagli Bibliografici
Autori principali:	Yitong Weng, Bing Ji
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	The Prostate
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy
di: Michal Jirásko, et al.
Pubblicazione: (2024)

Altered Glycosylation of PSA in Prostate Cancer Tissue
di: Hannu Koistinen, et al.
Pubblicazione: (2025)

Beyond Baseline: Serial PSA Measurements and Risk Stratification for Prostate Cancer
di: Anwar E. Ahmed, et al.
Pubblicazione: (2025)

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer
di: Fabian Falkenbach, et al.
Pubblicazione: (2025)

Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients
di: Mike Wenzel, et al.
Pubblicazione: (2024)

A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA
di: Penglu Yang, et al.
Pubblicazione: (2025)

Association of Weight Loss and BMI on PSA Levels and Overall Survival in Veterans With Metastatic Castrate‐Resistant Prostate Cancer
di: Nicholas Fedele, et al.
Pubblicazione: (2025)

Prostate Volume and PSA‐Density Estimation by Transabdominal Ultrasound: Prospective Evidence of Comparative Accuracy to MRI and Transrectal Ultrasound in Prostate Cancer Early Diagnostics
di: Liza M. Kurucz, et al.
Pubblicazione: (2025)

Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3–5 Lesions
di: Takanori Tokunaga, et al.
Pubblicazione: (2025)

Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease
di: Mark Kidd, et al.
Pubblicazione: (2025)

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy
di: Takeshi Tsutsumi, et al.
Pubblicazione: (2026)

The Effects of the Blood‐Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies
di: Hikari Miura, et al.
Pubblicazione: (2025)

Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer
di: Fabian Falkenbach, et al.
Pubblicazione: (2024)

Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
di: Eli Marie Grindedal, et al.
Pubblicazione: (2024)

Predictive Value of PSA Bounce Phenomenon after Stereotactic Body Radiation Therapy in a Large Population of Prostate Cancer Patients Treated By 1.5 T MR Guided Adaptive Technique
di: Andrea Romei, et al.
Pubblicazione: (2025)

PSA Density and Lesion Volume: Key Factors in Avoiding Unnecessary Biopsies for PI‐RADS 3 Lesions
di: Ali Ayranci, et al.
Pubblicazione: (2024)

LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA
di: Irena Abramovic, et al.
Pubblicazione: (2024)

Prostate Specific Antigen Density and Clinically‐Significant Prostate Cancer: The Influence of Prostatic Volume
di: Elizabeth Robinson, et al.
Pubblicazione: (2025)

Prostatic Surgery With Preservation of the Supramonticular Tissue Versus Standard Surgery for Benign Prostatic Hyperplasia: A Systematic Review
di: Giuston Mendoza‐Chuctaya, et al.
Pubblicazione: (2025)

Safety and Efficacy of Bipolar Transurethral Vaporization of the Prostate and Bipolar Transurethral Resection of the Prostate in the Management of Large Volume Benign Prostatic Hyperplasia: A Prospective Randomized Study
di: Amr M. Lotfy, et al.
Pubblicazione: (2026)

The Mediterranean Diet and Benign Prostatic Hyperplasia: A Pathway to Improved Urinary Health
di: İsa Dağlı, et al.
Pubblicazione: (2025)

Enhancing Diagnostic Accuracy in Prostate Oncology: A Multidimensional Perspective on Prostate Specific Antigen Density
di: Shengyi Chen, et al.
Pubblicazione: (2025)

Association of Escherichia coli Infection and fimh Virulence With Benign Prostatic Hyperplasia in Ghanaian Patients
di: Yvonne Anang, et al.
Pubblicazione: (2025)

Cáncer de Próstata. ¿Qué es el antígeno prostático específico?. (La biología del PSA)
di: Juan Fernando Uribe Arcila
Pubblicazione: (2007)

A west African ancestry‐associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening
di: Jian Gu, et al.
Pubblicazione: (2024)

Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment
di: Chris H.‐M. Wong, et al.
Pubblicazione: (2024)

Prostate‐Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone‐Sensitive Prostate Cancer Treated With Apalutamide
di: Christian Andrés Martínez Osorio, et al.
Pubblicazione: (2025)

Value of Systematic and MRI‐Ultrasound Fusion Prostate Biopsy in Different Prostate Specific Antigen (PSA) Levels
di: Solmaz Ohadian Moghadam, et al.
Pubblicazione: (2025)

Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy
di: Yuto Ono, et al.
Pubblicazione: (2025)

Probenecid and Eugenol Mitigate Testosterone Induced Benign Prostatic Hyperplasia by Targeting Uric Acid‐Induced Inflammation and Pro‐Survival Pathways
di: Nibrass Taher Abdali, et al.
Pubblicazione: (2025)

Editorial Comment on Beyond Total PSA : Clinical Significance of S2 , 3PSA % in Reducing Unnecessary Prostate Biopsies
di: Yusuke Goto
Pubblicazione: (2026)

Integrating Clinical and Societal Perspectives on Prostate Cancer Research: Addressing Key Limitations and Future Directions
di: Yuekun Fang, et al.
Pubblicazione: (2026)

Is Cystolitholapaxy Sufficient in Patients With Bladder Stones Secondary to Benign Prostatic Obstruction?
di: Mert Hamza Özbilen, et al.
Pubblicazione: (2026)

Prognostic Impact of Initial Prostate Specific Antigen Half‐Life After Abiraterone Acetate in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: Who May Need Triplet Therapy?
di: Kotaro Suzuki, et al.
Pubblicazione: (2026)

c‐Kit‐Mediated PI3K/AKT and Wnt/β‐Catenin Signaling Drives Resistance to 5α‐Reductase Inhibitors in Benign Prostatic Hyperplasia
di: Jun Zhu, et al.
Pubblicazione: (2025)

Mortality and Additional Treatment Rates in Pathologically High‐Risk Prostate Cancer With Prostate‐Specific Antigen Persistence at Robot‐Assisted Radical Prostatectomy: Long‐Term Report From Single Tertiary Referral Center
di: Alessandro Bertini, et al.
Pubblicazione: (2025)

Correction to “[Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study ( The Prostate , 2025). https://doi.org/10.1002/pros.70071]”
Pubblicazione: (2026)

Multicenter External Validation and Optimization of a Proposed Nomogram for Prostate‐Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence
di: Laura Chamorro Castillo, et al.
Pubblicazione: (2025)

Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study
di: Giulio Bevilacqua, et al.
Pubblicazione: (2025)

The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate
di: Yifu Shi, et al.
Pubblicazione: (2025)

Documenti analoghi

Documenti analoghi